ponatinib (Iclusig)

From Aaushi
Jump to navigation Jump to search

Introduction

Marketing suspended October 31, 2013 due to serious risk of venous thromboembolism.[4]

Indications

Dosage

once daily

Adverse effects

Mechanism of action

Notes

More general terms

References

  1. FDA News Release: Dec. 14, 2012 FDA approves Iclusig to treat two rare types of leukemia http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm332252.htm
  2. Cortes JE et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 2012 Nov 29; 367:2075. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23190221
  3. 3.0 3.1 FDA MedWatch. October 11,2013 Inclusig (Ponatinib): Drug Safety Communication - Increased Reports Of Serious Blood Clots In Arteries And Veins. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm370971.htm
    FDA MedWatch. October 31,2013 Iclusig (Ponatinib): Drug Safety Communication - Increased Reports Of Serious Blood Clots In Arteries And Veins. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm370971.htm
  4. 4.0 4.1 4.2 FDA Drug Safety Communication: Dec 20, 2013 FDA requires multiple new safety measures for leukemia drug Iclusig; company expected to resume marketing. http://www.fda.gov/Drugs/DrugSafety/ucm379554.htm